Results 51 to 60 of about 108 (70)

Impact of secretin receptor homo-dimerization on natural ligand binding. [PDF]

Nat Commun
Harikumar KG, Piper SJ, Christopoulos A, Wootten D, Sexton PM, Miller LJ.   +5 more
europepmc   +1 more source

Cholesterol-dependent dynamic changes in the conformation of the type 1 cholecystokinin receptor affect ligand binding and G protein coupling. [PDF]

PLoS Biol
Harikumar KG, Zhao P, Cary BP, Xu X, Desai AJ, Dong M, Mobbs JI, Toufaily C, Furness SGB, Christopoulos A, Belousoff MJ, Wootten D, Sexton PM, Miller LJ.   +13 more
europepmc   +1 more source

What is the pipeline for future medications for obesity? [PDF]

Int J Obes (Lond)
Melson E, Ashraf U, Papamargaritis D, Davies MJ.   +3 more
europepmc   +1 more source

Anti-osteoporotic treatments in the era of non-alcoholic fatty liver disease: friend or foe. [PDF]

Front Endocrinol (Lausanne)
Chondrogianni ME, Kyrou I, Androutsakos T, Flessa CM, Menenakos E, Chatha KK, Aranan Y, Papavassiliou AG, Kassi E, Randeva HS.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight

American Journal of Physiology - Endocrinology and Metabolism, 2016
This study aims to elucidate the mechanism behind the potent weight loss induced by dual amylin and calcitonin receptor agonists (DACRA) through comparison of the novel DACRA KBP-088 with the amylinomimetic davalintide with regard to in vitro receptor pharmacology and in vivo efficacy on food intake and body weight. KBP-088 and davalintide were tested
Morten Karsdal, Kim Henriksen
exaly   +3 more sources

DACRA induces profound weight loss, satiety control, and increased mitochondrial respiratory capacity in adipose tissue

International Journal of Obesity
Dual amylin and calcitonin receptor agonists (DACRAs) are therapeutic candidates in the treatment of obesity with beneficial effects on weight loss superior to suppression of food intake. Hence, suggesting effects on energy expenditure by possibly targeting mitochondria in metabolically active tissue.Male rats with HFD-induced obesity received a DACRA,
Morten Karsdal, Anna Thorsø Larsen, Louise Dalgaard   +2 more
exaly   +5 more sources

1995-P: Optimization of DACRA Dosing Frequency—The Balance between Efficacy and Tolerability

Diabetes, 2019
Potent dual amylin and calcitonin receptor agonists (DACRAs) are novel candidates for treatment of T2D and obesity due to their beneficial effects on body weight, blood glucose and insulin sensitivity. Notably, DACRAs activate the receptors for a prolonged time period resulting in metabolic effects superior to those of amylin.
ANNA T. LARSEN, KIM V. ANDREASSEN, NINA SONNE, MORTEN ASSER KARSDAL, KIM HENRIKSEN   +4 more
openaire   +1 more source

2016-P: High Dose DACRA Treatment Improves Glucose Homeostasis, without Additional Weight Loss

Diabetes, 2019
KBP is a Dual Amylin and Calcitonin Receptor Agonist (DACRA). DACRAs have shown efficacy on weight loss and glucose control in rats. However, it is unclear whether the maximum effect has been reached. High Fat Diet (HFD, 60% fat) fed male Sprague-Dawley rats entered a dose escalation regimen ending at 5 (normal dose), 50 or 500 µg/kg daily KBP (n=10 ...
NINA SONNE, ANNA T. LARSEN, KIM V. ANDREASSEN, MORTEN ASSER KARSDAL, KIM HENRIKSEN   +4 more
openaire   +1 more source

Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats

American Journal of Physiology - Endocrinology and Metabolism, 2023
Anna Thorsø Larsen, Daniel Guldager Kring Rasmussen, Federica Genovese   +2 more
exaly  

Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss

European Journal of Pharmacology, 2023
Morten Karsdal, Anna Thorsø Larsen
exaly